The present disclosure is in the field of pharmaceutical compositions suitable for the treatment of diseases in mammals. The disclosure provides novel compositions comprising non-pathogenic fecal microbes or a sterile fecal filtrate for treating Parkinson's disease and related diseases. The disclosure also provides methods for treating a subject with the compositions disclosed herein.

The present disclosure is in the field of pharmaceutical compositions suitable for the treatment of diseases in mammals. The disclosure provides novel compositions comprising non-pathogenic fecal microbes for treating multiple sclerosis and related diseases. The disclosure also provides methods for treating a subject with the compositions disclosed herein.

The present disclosure is in the field of pharmaceutical compositions suitable for the treatment of diseases in mammals. The disclosure provides novel compositions comprising non-pathogenic fecal microbes for treating multiple sclerosis and related diseases. The disclosure also provides methods for treating a subject with the compositions disclosed herein.

Described is a formulation and method for reducing and treating bacterial infections in humans and animals with digested or non-digested extracellular matrix materials derived from non-epithelial and epithelial tissues.

Method and device to treat cancer after surgery in the gastrointestinal tract. The device can be used in a method comprising of removing cancerous cells from a cancerous site on a tissue or organ of a patient, positioning a biodegradable device having a cancer treatment agent to cover the cancerous site, securing the biodegradable device to the cancerous site such that an outer wall of the device extends across the cancerous site, and leaving the biodegradable device at the cancerous site for treatment of microcells left adjacent to the cancerous site.

Method and device to treat cancer after surgery in the gastrointestinal tract. The device can be used in a method comprising of removing cancerous cells from a cancerous site on a tissue or organ of a patient, positioning a biodegradable device having a cancer treatment agent to cover the cancerous site, securing the biodegradable device to the cancerous site such that an outer wall of the device extends across the cancerous site, and leaving the biodegradable device at the cancerous site for treatment of microcells left adjacent to the cancerous site.

Methods of treatment are provided herein, including administration of a population cells modified to enforce expression of an E-selectin and/or an L-selectin ligand, the modified cell population having a cell viability of at least 70% after a treatment to enforce such expression.

Methods of treatment are provided herein, including administration of a population cells modified to enforce expression of an E-selectin and/or an L-selectin ligand, the modified cell population having a cell viability of at least 70% after a treatment to enforce such expression.

Provided herein are compositions of anorectal transition zone stem cells, including multipotent and progenitor cells, to treat anal fistulas, for example, refractory complex perianal fistulas associated with Crohn's disease or of unknown aetiology. Also provided are pharmaceutical compositions of the anorectal transition zone stem cells, including multipotent and progenitor cells, in a pharmaceutically acceptable carrier.

Provided herein are compositions of anorectal transition zone stem cells, including multipotent and progenitor cells, to treat anal fistulas, for example, refractory complex perianal fistulas associated with Crohn's disease or of unknown aetiology. Also provided are pharmaceutical compositions of the anorectal transition zone stem cells, including multipotent and progenitor cells, in a pharmaceutically acceptable carrier.